Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, rose in value on Friday, 05/13/22, with the stock price up by 7.19% to the previous day’s close as strong demand from buyers drove the stock to $3.80.
Actively observing the price movement in the last trading, the stock closed the session at $3.55, falling within a range of $3.70 and $3.98. The value of beta (5-year monthly) was 1.08. Referring to stock’s 52-week performance, its high was $11.59, and the low was $3.49. On the whole, AVDL has fluctuated by -45.17% over the past month.
With the market capitalization of Avadel Pharmaceuticals plc currently standing at about $238.83 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 07, 2022 – Mar 11, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.42, which is expected to increase to -$0.39 for fiscal year -$1.37 and then to about -$1.05 by fiscal year 2022. Data indicates that the EPS growth is expected to be -1,153.80% in 2022, while the next year’s EPS growth is forecast to be 23.40%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AVDL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
10 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 10 recommend it as a Buy and 0 called the AVDL stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AVDL currently trading nearly -25.97% and -39.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.05, while the 7-day volatility ratio is showing 10.68% which for the 30-day chart, stands at 10.30%. Furthermore, Avadel Pharmaceuticals plc (AVDL)’s beta value is 1.13, and its average true range (ATR) is 0.45.
A comparison of Avadel Pharmaceuticals plc (AVDL) with its peers suggests the former has fared considerably weaker in the market. AVDL showed an intraday change of 7.19% in last session, and over the past year, it shrunk by -50.46%%. In comparison, Eagle Pharmaceuticals Inc. (EGRX) has moved lower at -0.45% on the day and was up 5.14% over the past 12 months. On the other hand, the price of DURECT Corporation (DRRX) has risen 2.33% on the day. The stock, however, is off -76.73% from where it was a year ago. Additionally, there is a gain of 4.36% for Heron Therapeutics Inc. (HRTX) in last trading while the stock has seen an overall depriciation of -74.08%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for Avadel Pharmaceuticals plc (NASDAQ:AVDL) indicates that the trading volumes over the past 10 days have averaged 0.42 million and over the past 3 months, they’ve averaged 625.15K. According to company’s latest data on outstanding shares, there are 58.62 million shares outstanding.
Nearly 1.07% of Avadel Pharmaceuticals plc’s shares belong to company insiders and institutional investors own 60.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.16 million shares as on Dec 14, 2021, resulting in a short ratio of 9.2. According to the data, the short interest in Avadel Pharmaceuticals plc (AVDL) stood at 7.09% of shares outstanding as of Dec 14, 2021; the number of short shares registered in Nov 14, 2021 reached 4.78 million. The stock has fallen by -52.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AVDL stock heading into the next quarter.